Schisandrin B


Dibenzocyclooctadiene lignan with pleiotropic antioxidant, hepatoprotective, anti-inflammatory, and cytoprotective activity

A principal bioactive dibenzocyclooctadiene lignan isolated from the fruit of Schisandra chinensis, distinguished by potent Nrf2-dependent antioxidant induction, NF-kB suppression, mitochondrial protective activity, and hepatoprotective efficacy across multiple preclinical models of chemical, ischemic, and metabolic liver injury.

Abstract

Schisandrin B (Sch B), also designated gamma-schisandrin, is the most pharmacologically characterized dibenzocyclooctadiene lignan isolated from the dried ripe fruit of Schisandra chinensis (Turcz.) Baill., a climbing vine of the family Schisandraceae with a history of use in traditional Chinese medicine spanning more than two millennia under the name wuweizi (five-flavor berry). Among the more than 30 structurally related lignans present in the Schisandra fruit, Schisandrin B has attracted the greatest research attention owing to a convergence of potent antioxidant, anti-inflammatory, hepatoprotective, cardioprotective, and neuroprotective activities demonstrated across a substantial body of in vitro and in vivo preclinical literature. The compound acts principally through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor and its downstream antioxidant response element (ARE)-dependent gene program, producing upregulation of glutathione S-transferase, heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase, and catalase. Concurrently, Schisandrin B suppresses NF-kB nuclear translocation and downstream proinflammatory cytokine expression (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) through inhibition of IkB-alpha degradation and suppression of MAPK cascade phosphorylation at c-Raf, MEK, ERK, JNK, and p38 nodes. Additional characterized mechanisms include enhancement of mitochondrial glutathione antioxidant status and heat shock protein induction, activation of the SIRT1/PI3K/Akt and AMPK/mTOR signaling axes, suppression of ferroptosis through upregulation of SLC7A11, GPX4, and FTH1, and modulation of pregnane X receptor (PXR)-mediated bile acid metabolism. The compound also exhibits preclinical cardioprotective activity against doxorubicin cardiotoxicity and angiotensin II-induced cardiac fibrosis, and neuroprotective activity against amyloid-beta-induced neuronal dysfunction, scopolamine-induced amnesia, and cisplatin-induced neurotoxicity. The compound has not been evaluated in human clinical trials as an isolated entity; all pharmacological and safety characterization derives from preclinical studies and from clinical experience with Schisandra chinensis fruit extracts and the semi-synthetic derivative bifendate (dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate). Preclinical toxicology in dogs has demonstrated dose-dependent plasma accumulation on repeated administration, and in vitro studies at high concentrations have identified paradoxical hepatotoxicity in mouse hepatocytes and macrophages, indicating that the therapeutic window requires careful characterization before clinical translation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph